echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Potential "first-in-class" therapy targeting a new immune checkpoint protein enters the clinic

    Potential "first-in-class" therapy targeting a new immune checkpoint protein enters the clinic

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 12, 2021, Immune-Onc Therapeutics announced that the US FDA has approved the IND application for IO-108, which is a potential for targeting leukocyte immunoglobulin-like receptor B2 (LILRB2, also known as ILT4) The "first-in-class" new antibody is used to treat solid tumors


    IO-108 can bind to LILRB2 with high affinity and specificity to block the interaction of LILRB2 with a variety of ligands involved in cancer-related immunosuppression


    Pre-clinical studies have shown that as a single-agent treatment, IO-108 can reverse the anti-inflammatory bone marrow cell phenotype and promote the differentiation of monocytes into pro-inflammatory dendritic cells


    ▲Operation mechanism of IO-108 (picture source: Immune-Onc official website)

    The multi-center, dose-escalating phase 1 clinical trial will include a single-agent cohort and a combination therapy cohort, and will evaluate the safety of IO-108 as a single-agent treatment and the combination of anti-PD-1 therapy Keytruda (pembrolizumab).


    Dr.


    Reference materials:

    [1] Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Advanced Solid Tumors.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.